Application of the Kaiser score on contrast-enhanced mammography in the differential diagnosis of breast lesions: comparison with breast magnetic resonance imaging.

BACKGROUND

The Kaiser score (KS) as a clinical decision rule has been proven capable of enhancing the diagnostic efficiency for suspicious breast lesions and obviating unnecessary benign biopsies. However, the consistency of KS in contrast-enhanced mammography (CEM-KS) and KS on magnetic resonance imaging (MRI-KS) is still unclear. This study aimed to evaluate and compare the diagnostic efficacy and agreement of CEM-KS and MRI-KS for suspicious breast lesions.

METHODS

This retrospective study included 207 patients from April 2019 to June 2022. The radiologists assigned a diagnostic category to all lesions using the Breast Imaging Reporting and Data System (BI-RADS). Subsequently, they were asked to assign a final diagnostic category for each lesion according to the KS. The diagnostic performance was evaluated by the area under the receiver operating characteristic curve (AUC). The agreement in terms of the kinetic curve and the KS categories for CEM and MRI were evaluated via the Cohen kappa coefficient.

RESULTS

The AUC was higher for the CEM-KS category assignment than for the CEM-BI-RADS category assignment (0.856 . 0.776; P=0.047). The AUC was higher for MRI-KS than for MRI-BI-RADS (0.841 . 0.752; P =0.015). The AUC of CEM-KS was not significantly different from that of MRI-KS (0.856 . 0.841; P=0.538). The difference between the AUCs for CEM-BI-RADS and MRI-BI-RADS was not statistically significant (0.776 . 0.752; P=0.400). The kappa agreement for the characterization of suspicious breast lesions using CEM-KS and MRI-KS was 0.885.

CONCLUSIONS

The KS substantially improved the diagnostic performance of suspicious breast lesions, not only in MRI but also in CEM. CEM-KS and MRI-KS showed similar diagnostic performance and almost perfect agreement for the characterization of suspicious breast lesions. Therefore, CEM holds promise as an alternative when breast MRI is not available or contraindicated.